Leading up to IVI’s launch in September 2016, funding was provided solely by Precision Medicine Group. Active recruitment of funding members is now underway, with representation being sought from insurers, providers, manufacturers, and patient advocacy groups. Current partners now include AbbVie, Amgen, Biotechnology Innovation Organization, Bristol-Myers Squibb, Genentech, Merck, National Pharmaceutical Council, Pfizer, PhRMA, Sanofi, and UCB. We look forward to expanding this support across all stakeholder audiences in an effort to enhance value, innovation, and choice across the health care system. Funding is provided in support of IVI’s mission and core objectives, but funding does not equate to a voting seat on the Strategic Advisory Panel that steers IVI’s research agenda.
For more information on how to get involved in finding solutions to the challenge of achieving high-value care, please e-mail us at firstname.lastname@example.org.